Abstract
Objective
The objective was to evaluate diagnostic performance of dynamic susceptibility-contrast
perfusion-weighted imaging, diffusion-weighted imaging, and 18F-fluorodeoxyglucose positron emission tomography in differentiating primary central
nervous system lymphoma (PCNSL) and glioblastoma.
Materials and methods
Twenty-three glioblastomas and 11 PCNSLs were analyzed with uncorrected cerebral blood
volume (CBV) ratio, fifth percentile value of cumulative apparent diffusion coefficient
histogram (ADC5%), and maximum standardized uptake value (SUVmax) using regions of interest created semiautomatically on enhancing areas.
Results
Uncorrected CBV ratio was highly capable of differentiating PCNSL from glioblastoma,
as well as SUVmax and ADC5%.
Conclusions
Uncorrected CBV ratio demonstrates high diagnostic performance comparable to SUVmax.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical ImagingAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma: a surveillance, epidemiology, and end results analysis.Cancer. 2002; 95: 1504-1510
- Primary central nervous system lymphoma.Arch Pathol Lab Med. 2008; 132: 1830-1834
- Primary central nervous system lymphoma: immunohistochemical profile and prognostic significance.Neuropathology. 2010; 30: 232-240
- Brain tumors.N Engl J Med. 2001; 344: 114-123
- Treatment of malignant glioma: a problem beyond the margins of resection.J Cancer Res Clin Oncol. 2001; 127: 217-225
- Current management of primary central nervous system lymphoma.Int J Radiat Oncol Biol Phys. 2010; 76: 666-678
- Distinguishing of primary cerebral lymphoma from high-grade glioma with perfusion-weighted magnetic resonance imaging.Neurosci Lett. 2003; 338: 119-122
- Perfusion and diffusion MR imaging in enhancing malignant cerebral tumors.Eur J Radiol. 2006; 58: 394-403
- Primary central nervous system lymphoma and atypical glioblastoma: multiparametric differentiation by using diffusion-, perfusion-, and susceptibility-weighted MR imaging.Radiology. 2014; 272: 843-850
- Lymphomas and high-grade astrocytomas: comparison of water diffusibility and histologic characteristics.Radiology. 2002; 224: 177-183
- Lymphomas and glioblastomas: differences in the apparent diffusion coefficient evaluated with high b-value diffusion-weighted magnetic resonance imaging at 3T.Eur J Radiol. 2012; 81: 339-344
- 18F-FDG PET of common enhancing malignant brain tumors.AJR Am J Roentgenol. 2008; 190: W365-W369
- Differentiation of newly diagnosed glioblastoma multiforme and intracranial diffuse large B-cell Lymphoma using (11)C-methionine and (18)F-FDG PET.Clin Nucl Med. 2012; 37: 843-849
- The diagnostic role of (18)F-FDG PET for primary central nervous system lymphoma.Ann Nucl Med. 2014; 28: 603-609
- Does adding FDG-PET to MRI improve the differentiation between primary cerebral lymphoma and glioblastoma? Observer performance study.Ann Nucl Med. 2011; 25: 432-438
- Relation between FDG uptake and apparent diffusion coefficients in glioma and malignant lymphoma.Ann Nucl Med. 2012; 26: 262-271
- Differentiation of primary central nervous system lymphomas and glioblastomas: comparisons of diagnostic performance of dynamic susceptibility contrast-enhanced perfusion MR imaging without and with contrast-leakage correction.AJNR Am J Neuroradiol. 2013; 34: 1145-1149
- Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not.AJNR Am J Neuroradiol. 2006; 27: 859-867
- Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial.Radiology. 2014; 271: 200-210
- Image thresholding by minimizing the measures of fuzziness.Pattern Recogn. 1995; 28: 41-51
- Differentiation of true progression from pseudoprogression in glioblastoma treated with radiation therapy and concomitant temozolomide: comparison study of standard and high-b-value diffusion-weighted imaging.Radiology. 2013; 269: 831-840
- Studies of primary central nervous system lymphoma with fluorine-18-fluorodeoxyglucose positron emission tomography.J Nucl Med. 1992; 33: 532-536
- Imaging gliomas with positron emission tomography and single-photon emission computed tomography.Semin Nucl Med. 2003; 33: 148-162
- Primary central nervous system lymphoma: radiologic–pathologic correlation.Radiographics. 1997; 17: 1497-1526
- Molecular pathogenesis of primary central nervous system lymphoma.Neurosurg Focus. 2006; 21: E1-E5
- Malignant lymphomas.in: Deckert M Paulus W WHO classification of tumours of the central nervous system. 4th ed. IARC Press, Lyon, France2007: 188-192
- The blood–brain barrier in primary CNS lymphomas: ultrastructural evidence of endothelial cell death.Neuro-Oncology. 1999; 1: 89-100
- Correlation of computed tomography with the histopathology of primary malignant lymphoma of the brain.Neuroradiology. 1992; 34: 36-42
- Angiogenesis in brain tumors; pathobiological and clinical aspects.J Neuro-Oncol. 1997; 32: 253-265
- The 39 steps: evading error and deciphering the secrets for accurate dynamic susceptibility contrast MRI.NMR Biomed. 2013; 26: 913-931
Article info
Publication history
Published online: December 11, 2014
Accepted:
December 6,
2014
Received in revised form:
November 19,
2014
Received:
September 22,
2014
Footnotes
☆Conflict of interest: none to declare.
Identification
Copyright
© 2015 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
